Sarepta Therapeutics, Inc. (SRPT)

NMS – Real vaqt narxi. Valyuta: USD

18.38

+0.16 (0.88%)

Bozor ochiq: Aug 12, 2026, 3:26 PM EDT

18.33

+0.11 (0.61%)

Oldingi bozordan keyin: Aug 11, 2026, 7:45 PM EDT

06.08.2026

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.

06.08.2026

Sarepta Therapeutics Q2 Earnings Call Highlights

Sarepta Therapeutics NASDAQ: SRPT reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted GAAP operating income of $13 million and non-GAAP operating income of $86 million, while increasing cash and investments by approximately $197 million during the quarter to $945 million.

06.08.2026

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

06.08.2026

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $2.02 per share a year ago.

06.08.2026

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

05.08.2026

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026. “As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients, and the significant opportunities ahead,” said Michael Severino, MD, chief executive officer, Sarepta Therapeutics. “Our second quarter results, including $328.7 m.

Videolar

No Data

There is no data to display

Press-relizlar

05.08.2026

Sarepta Therapeutics, Inc. (SRPT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Sarepta Therapeutics, Inc. (SRPT)

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

Sarepta Therapeutics Q2 Earnings Call Highlights

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Videolar

No Data

Press-relizlar

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

Sarepta Therapeutics Q2 Earnings Call Highlights

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Videolar

No Data

Press-relizlar

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Search stocks

Sarepta Therapeutics, Inc. (SRPT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Sarepta Therapeutics, Inc. (SRPT)

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

Sarepta Therapeutics Q2 Earnings Call Highlights

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Videolar

No Data

Press-relizlar

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

Sarepta Therapeutics Q2 Earnings Call Highlights

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Videolar

No Data

Press-relizlar

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments